How do I know if my BPC-157 is real?

Test a sample from your own vial or batch. Mass spectrometry should find the BPC-157 mass, HPLC then gives purity, and an amount test reports milligrams of peptide against the label. A neat label, a hologram or a seller's certificate for a different batch cannot tell you what is in your vial; only a result on your own sample can.

What mass should a BPC-157 COA show?

PubChem lists BPC-157 as C62H98N16O22 with an average mass of 1419.5 g/mol and a monoisotopic mass of 1418.70 Da. The certificate should show the expected value, the measured value and which kind of mass it used. A matching mass with a purity line that names no method is still incomplete, so check both.

Why does my BPC-157 test show less than 10 mg in a 10 mg vial?

Often because the label counts powder, not peptide. Synthetic peptides carry counter-ions such as trifluoroacetate or acetate, plus some water, and one study measured trifluoroacetate at up to 35% of a peptide salt's weight. A vial can also simply be underfilled. A report that gives peptide content and counter-ion content separately tells you which explanation fits.

Is BPC-157 acetate different from BPC-157?

The peptide is the same molecule; acetate is a counter-ion that adds weight to the powder. The US FDA listed BPC-157 acetate and BPC-157 free base separately for its 2026 advisory committee consultation. For testing, ask which form the vial contains and whether the label amount refers to the peptide or to the salt.

Can BPC-157 break down before it is tested?

Yes. A 2026 review names cleavage of the bond between its two aspartic acids, positions 10 and 11, as its main chemical weak point under acidic and neutral conditions. A test that finds fragments matching the two halves of that bond, confirmed by LC-MS mass, points to degradation rather than a wrong peptide.

One of the 30 compound testing profiles

BPC-157

BPC-157 is a 15-amino-acid peptide (C62H98N16O22, average mass 1419.5 g/mol, sequence GEPPPGKPADDAGLV); a test should confirm that mass, look for cleavage and aspartimide by-products at its Asp-Asp pair, and measure peptide content separately from salt and water.

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein fragment that, according to a 2026 review, lacks the evidence needed for investigational or approved use under any major regulatory framework (Mateescu et al., Pharmaceutics, 2026).

Test your BPC-157

Identity card

Formula: C62H98N16O22
Average mass: 1,419.5 g/mol
Monoisotopic mass: 1,418.7 Da
Length: 15 residues
Modifications: None: free N-terminal amine and free C-terminal acid (H-GEPPPGKPADDAGLV-OH)
Also sold as: Body Protection Compound 157, PL 14736
Sequence: GEPPPGKPADDAGLV
Note: PubChem gives 1419.5 g/mol average and 1418.70415882 Da monoisotopic, recorded here as 1418.70, with the line notation H-GEPPPGKPADDAGLV-OH. Bepecin, BPC 15 and PL-14736 are listed synonyms of the same record.

Source: PubChem CID 9941957, BPC-157.

Check a certificate's mass against these values with the mass checker, prefilled for BPC-157.

What usually goes wrong with BPC-157. Documented failure modes, with sources.

Cleavage at the Asp10 to Asp11 bond

BPC-157 contains no methionine, cysteine, tryptophan, asparagine or glutamine, so the usual oxidation and deamidation routes do not apply. A 2026 review names hydrolysis of the aspartyl bond at the Asp10 to Asp11 junction as its main chemical weak point under acidic and neutral conditions (Mateescu et al., Pharmaceutics, 2026). Cleavage there leaves two fragments with their own masses, which LC-MS can name and HPLC shows as separate peaks.

Aspartimide by-products from synthesis

The same pair causes trouble during manufacture: in Fmoc solid-phase synthesis, Asp-Asp is among the sequences particularly prone to aspartimide formation (Behrendt et al., Journal of Peptide Science, 2016). The aspartimide ring reopens into a racemised mixture of alpha- and beta-aspartyl peptides, and the beta forms are notoriously difficult to separate from the target (Kong et al., ChemBioChem, 2025). A beta-aspartyl peptide has exactly the mass of BPC-157, so a mass-only identity pass cannot exclude it; only a chromatographic method that resolves it can show how much is there.

Acetate, free base and trifluoroacetate

BPC-157 circulates in more than one salt form: the US FDA's planned advisory committee consultation listed BPC-157 acetate and BPC-157 free base as separate substances (Mateescu et al., 2026). Material straight from solid-phase synthesis is usually a trifluoroacetate salt, and in one study trifluoroacetate reached 35% of the total weight of the peptide salts tested (Erckes et al., Pharmaceuticals, 2025). A label that counts salt and water as peptide overstates the BPC-157 present without any substitution at all.

No pharmaceutical-grade reference

The US FDA says BPC-157 may have complexities with regard to peptide-related impurities and characterisation of the active ingredient (FDA, bulk substances with safety risks). The 2026 review adds that no GMP product suitable for clinical use exists and that a pharmaceutical-grade drug substance with characterised identity, purity and stability is lacking (Mateescu et al., 2026). There is no official reference product, so every amount result rests on the reference standard the laboratory chose, which should itself be identified and assigned a content.

What we check in BPC-157. Silent, with captions.

Which tests matter most

LC-MSConfirms the 1419.5 mass and names fragments from Asp10 to Asp11 cleavage or synthesis deletions.
HPLC-UVThe purity method the 2026 review lists, and the routine way to see beta-aspartyl forms that share the target's mass.
Amino acid analysisListed with mass spectrometry as an identity method for BPC-157, and gives peptide content regardless of salt form.
Counter-ion contentShows whether the powder is acetate, trifluoroacetate or free base, which changes how much of the weighed mass is peptide.

Reading BPC-157 results

At about 1.4 kDa, BPC-157 gives a simple mass spectrum, so a certificate with no measured mass, or no statement of whether it is average or monoisotopic, is leaving out easy evidence. The mass checker computes the expected value from the sequence. An amount result is milligrams of BPC-157 against a reference standard, not powder weight; the net peptide content lesson and content calculator show why the two differ.

The four prolines, three of them in a row at positions 3 to 5, and the Asp-Asp pair give synthesis variants that elute close to the main peak. The 2026 review sets the analytical baseline as identity by amino acid analysis and mass spectrometry, and purity by reverse-phase HPLC with UV or charged aerosol detection (Mateescu et al., 2026).

Public Tested.ph results

No public BPC-157 records yet

Each public BPC-157 record will appear here with its identity, HPLC purity and measured amount against the label, once the first vial is tested.

FIG 13Amount against the label

Questions about testing BPC-157

How do I know if my BPC-157 is real?: Test a sample from your own vial or batch. Mass spectrometry should find the BPC-157 mass, HPLC then gives purity, and an amount test reports milligrams of peptide against the label. A neat label, a hologram or a seller's certificate for a different batch cannot tell you what is in your vial; only a result on your own sample can.
What mass should a BPC-157 COA show?: PubChem lists BPC-157 as C62H98N16O22 with an average mass of 1419.5 g/mol and a monoisotopic mass of 1418.70 Da. The certificate should show the expected value, the measured value and which kind of mass it used. A matching mass with a purity line that names no method is still incomplete, so check both.
Why does my BPC-157 test show less than 10 mg in a 10 mg vial?: Often because the label counts powder, not peptide. Synthetic peptides carry counter-ions such as trifluoroacetate or acetate, plus some water, and one study measured trifluoroacetate at up to 35% of a peptide salt's weight. A vial can also simply be underfilled. A report that gives peptide content and counter-ion content separately tells you which explanation fits.
Is BPC-157 acetate different from BPC-157?: The peptide is the same molecule; acetate is a counter-ion that adds weight to the powder. The US FDA listed BPC-157 acetate and BPC-157 free base separately for its 2026 advisory committee consultation. For testing, ask which form the vial contains and whether the label amount refers to the peptide or to the salt.
Can BPC-157 break down before it is tested?: Yes. A 2026 review names cleavage of the bond between its two aspartic acids, positions 10 and 11, as its main chemical weak point under acidic and neutral conditions. A test that finds fragments matching the two halves of that bond, confirmed by LC-MS mass, points to degradation rather than a wrong peptide.

Sources

Mateescu DM et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5), Pharmaceutics (PMC)
Certain bulk drug substances for use in compounding that may present significant safety risks, US Food and Drug Administration
Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27, Journal of Peptide Science (PMC)
Kong MJW, van den Braak TJHP, Neumann K. Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis. ChemBioChem. 2025;26(18):e202500490, ChemBioChem (PMC)
Erckes V et al. Towards a Consensus for the Analysis and Exchange of TFA as a Counterion in Synthetic Peptides. Pharmaceuticals. 2025;18(8):1163, Pharmaceuticals (PMC)
PubChem CID 9941957, BPC-157, National Library of Medicine

Last reviewed 6 Oct 2026.